Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 04 / 01
Fangda Advises Jiangsu Marching Power on Acquisition of Control of A-Share Listed Company CSD Water Service Co., Ltd.
2026 / 04 / 01
Fangda Partners Advises Lugard Capital on Aridge’s USD200 Million Financing Round
2026 / 03 / 31
Fangda assisted Ant Group in its acquisition of Bright Smart Securities (HK.1428)
2026 / 03 / 30
Fangda Advises Huaota Biopharmaceutical on Global Collaboration and Licensing Agreement with Almirall for a Novel Monoclonal Antibody in Medical Dermatology
2026 / 03 / 24
Fangda advises SeeYA Technology on its successful STAR Market listing
